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Abstract 
Malaria causes considerable morbidity and mortality among young children in malaria 
endemic areas worldwide. Anti-malarial antibodies are crucial determinants of 
Plasmodium falciparum infection outcome. In this study the levels of circulating 
immunoglobulin-G antibodies specific to crude Plasmodium falciparum antigens were 
determined by an  indirect enzyme-linked immunosorbent assay in a hospital based case-
control study, of children with varying malaria severity living in the rural area of Gedarif 
eastern Sudan and El-Obied west of Sudan. The aims were to investigate if 
immunoglobulin-G subclasses correlated with the clinical presentation of the disease and 
other malariometric indices among children exposed to seasonal and unstable 
Plasmodium falciparum transmission. The levels of circulating interleukin-10 and the 
genotypes of the single nucleotide polymorphism at position -1082 of IL-10 gene were 
also investigated in relation to malaria severity.  
The results revealed that individuals with severe malaria had significantly lower 
prevalence and levels of IgG1 and IgG4 as compared to those with uncomplicated 
malaria, suggesting a protective role for these molecules against severe malaria. The 
levels of IL-10 were lower in severe malaria patients as compared to those who presented 
with uncomplicated malaria, but no significant association was found between the 
specific alleles or genotypes in the -1082 A/G polymorphic site and any particular form 
of clinical malaria. 
The present data argue for protective roles for IgG1 and IgG4 antibodies and IL-10 
against severe malaria, but find no evidence supporting significant effect of the different 
alleles or genotypes at position (-1082A/G) of the IL-10 gene on protection from SM. 
  11
 
 
  :ﻤﺴﺘﺨﻠﺺاﻟ
واﻟﻮﻓﻴﺎت ﺑﻴﻦ اﻷﻃﻔﺎل ﻓﻲ اﻟﻤﻨﺎﻃﻖ اﻟﻤﻮﺑﺆة ﺑﺎﻟﻤﻼرﻳﺎ ﻓﻲ ﻣﺨﺘﺎف أرﺟﺎء  ﻤﺮاﺿﺔﺗﺴﺒﺐ اﻟﻤﻼرﻳﺎ ﻗﺪرًا ﻣﻌﺘﺒﺮًا ﻣﻦ اﻟ
ﻗﺪ ﺗﻢ ﻓﻲ هﺬﻩ .  ﺎﻟﻤﺘﺼﻮرة اﻟﻤﻨﺠﻠﻴﺔوﺗﻌﺘﺒﺮ اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻠﻤﻼرﻳﺎ ﻣﻦ اﻟﻤﺤﺪدات اﻟﻬﺎﻣﺔ ﻟﻨﺘﻴﺠﺔ اﻟﻌﺪوى ﺑ. اﻟﻌﺎﻟﻢ
 ﻟﻠﻤﺘﺼﻮرات اﻟﻤﻨﺠﻠﻴﺔاﻟﻤﻼرﻳﺎ ﻓﻲ اﻟﻤﺴﺘﺨﻠﺺ اﻟﺨﺎم ﻤﺴﺘﻀﺪات اﻟﻤﻀﺎدة ﻟ اﻟﺪراﺳﺔ ﻗﻴﺎس ﻣﺴﺘﻮﻳﺎت اﻷﺟﺴﺎم
ﻓﻲ ﻋﻴﻨﺔ ﻣﻦ اﻷﻃﻔﺎل اﻟﻤﺼﺎﺑﻴﻦ ﺑﺄﻋﺮاض ﻣﺘﺒﺎﻳﻨﺔ اﻟﻤﻘﺎﻳﺴﺔ ﺑﺎﻹﻣﺘﺼﺎص اﻟﻤﻨﺎﻋﻲ اﻟﻤﺮﺗﺒﻂ ﺑﺎﻹﻧﺰﻳﻢ ﺑﺈﺳﺘﺨﺪام ﻃﺮﻳﻘﺔ 
ﺮب ﻓﻲ ﻏ ﻟﻠﻤﻼرﻳﺎ ﻣﻘﺎرﻧﺔ ﺑﺎﻷﺻﺤﺎء اﻟﺬﻳﻦ ﻳﻘﻴﻤﻮن ﻓﻲ اﻟﻤﻨﺎﻃﻖ اﻟﺮﻳﻔﻴﺔ ﺣﻮاﻟﻲ اﻟﻘﻀﺎرف ﻓﻲ ﺷﺮق واﻷﺑﻴﺾ
  .اﻟﺴﻮدان
ﻠﻤﻼرﻳﺎ وﺳﻂ اﻷﻃﻔﺎل ﻟج واﻷﻋﺮاض اﻟﺴﺮﻳﺮﻳﺔ -اﻷﺟﺴﺎم اﻟﻤﻀﺎدةﻣﺴﺘﻮﻳﺎت ﺑﻴﻦ اﻟﻌﻼﻗﺔ اﻟﺪراﺳﺔ ﻟﻠﺘﻌﺮف ﻋﻠﻰ  ﺖهﺪﻓو
اﻟﻤﺴﺘﻮﻳﺎت ﺖ دراﺳﺔ اﻟﻌﻼﻗﺔ ﺑﻴﻦ آﺬﻟﻚ ﺗﻤ . ﻟﻠﻤﺘﺼﻮرات اﻟﻤﻨﺠﻠﻴﺔاﻟﻤﻮﺳﻤﻲ ﺸﺎر ﻓﻲ ﻣﻨﺎﻃﻖ اﻹﻧﺘﺻﺎﺑﺔ اﻟﻤﻌﺮﺿﻴﻦ ﻟﻼ
ﻓﻲ ( 2801- )رﻗﻢ ﻟﻨﻴﻮآﻠﻴﻮﺗﻴﺪة ﻟﻠﻘﻮاﻋﺪ اﻟﻨﺘﺮوﺟﻴﻨﻴﺔ ﻓﻲ ااﺛﻴﺔ رﺎط اﻟﻮواﻷﻧﻤ 01-اﻟﺠﺎرﻳﺔ ﻓﻲ اﻟﺪم ﻣﻦ اﻹﻧﺘﺮﻟﻴﻮآﻴﻦ
  .ﻤﺮﺿﻰ اﻟﻤﻼرﻳﺎ اﻟﺒﺴﻴﻄﺔﻣﻘﺎرﻧﺔ ﺑﻟﺪى اﻟﻤﺮﺿﻰ ﺑﺎﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ ﻣﻮرث هﺬا اﻟﺴﻴﺘﻮآﻴﻦ 
  
ﺗﻜﻮن أﻗﻞ ﻓﻲ  01-واﻻﻧﺘﺮﻟﻴﻮآﻴﻦ 4و ج 1ج-وﻣﺴﺘﻮﻳﺎت اﻷﺟﺴﺎم اﻟﻤﻀﺎدةﻧﺘﺸﺎر أوﺿﺤﺖ اﻟﺪراﺳﺔ أن ﻣﻌﺪﻻت اﻹ
ﺑﺎﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ ﻣﻘﺎرﻧﺔ ﻳﺎﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻤﻼرﻳﺎ اﻟﺒﺴﻴﻄﺔ ﻣﻤﺎ ﻳﺸﻴﺮ ﻟﻮﺟﻮد دور وﻗﺎﺋﻲ ﻟﻬﺬﻩ اﻷﺷﺨﺎص اﻟﻤﺼﺎﺑﻴﻦ 
ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻤﻼرﻳﺎ  01- ﻓﻘﺪ وﺟﺪت ﻣﺴﺘﻮﻳﺎت أﻗﻞ ﻟﻺﻧﺘﺮﻟﻴﻮآﻴﻦ. ﺿﺪ اﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔﺒﺮوﺗﻴﻨﺎت اﻟ
ﻴﻞ ﻳﺸﻴﺮ ﻹرﺗﺒﺎط وﺛﻴﻖ ﺑﻴﻦ وﻟﻜﻦ ﻟﻢ ﻳﺘﻢ اﻟﻌﺜﻮر ﻋﻠﻰ دﻟ, اﻟﻮﺧﻴﻤﺔ ﻣﻘﺎرﻧﺔ ﺑﺄوﻟﺌﻚ اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻤﻼرﻳﺎ اﻟﺒﺴﻴﻄﺔ
واﻷﻧﻤﺎط اﻟﺴﺮﻳﺮﻳﺔ  01-ﻣﻮرث اﻹﻧﺘﺮﻟﻴﻮآﻴﻦ ﻣﻦ( 2801- )اﻟﻨﻴﻮآﻠﻴﻮﺗﻴﺪة رﻗﻢ اﻟﻤﻜﻮﻧﺎت اﻟﻮراﺛﻴﺔ اﻟﻤﻮﺟﻮدة ﻓﻲ 
  .ﻟﻠﻤﻼرﻳﺎ
 4واﻟﻨﻮع ج 1ﻓﺄن ﻧﺘﺎﺋﺞ هﺬﻩ اﻟﺪراﺳﺔ ﺗﺪﻓﻊ ﻓﻲ إﺗﺠﺎﻩ أن هﻨﺎك دورًا وﻗﺎﺋﻴًﺎ ﻟﻸﺟﺴﺎم اﻟﻤﻀﺎدة ﻣﻦ اﻟﻨﻮع ج ﻴﻪ ﺑﻨﺎءًا ﻋﻠ
ﻤﻀﺎﻋﻔﺎت اﻟﻮﺧﻴﻤﺔ ﻟﻤﺮض اﻟﻤﻼرﻳﺎ، وﻟﻜﻦ ﻟﻴﺴﺖ هﻨﺎك دﻻﺋﻞ ﺗﺴﻨﺪ وﺟﻮد ﺗﺄﺛﻴﺮ اﻟﻣﻦ  01- ﻮآﻴﻦوآﺬﻟﻚ ﻟﻺﻧﺘﺮﻟﻴ
  . ﻋﻠﻰ اﻟﻮﻗﺎﻳﺔ ﻣﻦ اﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ 01-ﻟﻤﻮرث اﻹﻧﺘﺮﻟﻴﻮآﻴﻦ( 2801-)ﻹﺧﺘﻼف اﻟﻤﻜﻮﻧﺎت اﻟﻮراﺛﻴﺔ ﻓﻲ اﻟﻤﻮﻗﻊ 
 
 12 
 
List of Figures         Page 
1. Figure 1.1   The Global Distribution of Malaria Transmission Risk.  15 
 
 
2. Figure 1.2   The life cycle of Plasmodium falciparum.   18 
 
 
3. Figure 3.1.  General comparisons of IgG subclass levels between  
the study groups.      59 
 
 
4. Figure 3.2.  Comparisons of IgG levels between the patient groups. 60 
 
 
5.  Figure 3.3. Levels of circulating IL10 in the study groups of  malaria  
patients and healthy controls.     67 
 
 
List of Tables 
1. Table 3.1.   The demographic and malariological indices of the study 
  groups        56 
 
 
2. Table 3.2.  Antimalarial immunoglobulin-G subclass sera reactivity  
and risk of severe malaria.     61 
 
 
3. Table 3.3.   Demographic features of study II population   64 
 
 
4. Table 3.4   The Hardy-Weinberg Equilibrium for the interleukin-10  
(-1082 A/G) SNP in the study groups    65. 
 
5. Table 3.5   Estimation of odds ratios, assuming different modes  
of A/G alleles  inheritance.     66 
 
 
 
 
 13 
 
 
 
 
 
 
 
 
 
Chapter One  
 
Introduction to Malaria  
Immunity and Pathogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
1.1. Introduction to malaria:   
1.1.1. The global burden and distribution of malaria. 
Malaria is by far the world’s most important parasitic disease with a staggering global 
impact [1]. Current estimates indicate that, malaria threatens the lives of 3.2 billion, 
causes  between  350-500 million clinical episode and kills more than one million people 
each year [2, 3]. Most morbidity and mortality occur among the vulnerable children and 
women at child bearing age in the poorest communities of sub-Saharan Africa (Fig 1.1) 
[4]. Conventional approaches used to assess the impact of malaria seem inadequate, and 
the reported figures of incidence, morbidity, and mortality are likely to be largely 
underestimated [5]. Recent innovative approaches, exploiting satellite imagery and 
climatic modeling of malaria transmission levels, further support this view [6-9].   
In addition to its direct heavy toll on health, malaria has immense socio-economic 
impact, and it has long been recognized that malarious communities are impoverished 
communities. This is clearly evidenced by the fact that, malaria endemic countries are the 
least developed ones with the lowest rates of economic growth [10].  The disease is 
responsible for around 1.3 % reduction in the overall annual economic growth rates in 
countries with high malaria endemicity. Malaria impedes economic through its effects on 
worker productivity, school performance and medical costs [10-13].  
The global distribution and clinical patterns of malaria are widely variable and are largely 
determined by the local levels of parasite transmission which are influenced by several 
biological and environmental factors [7, 14]. Genetic characteristics of the host, the 
parasite, and the vector as well as the environmental factors including socioeconomic, 
and the malaria control measures contribute differently to the disease distribution.  
 15 
 
Conventionally, levels of transmission are measured by estimating the entomological 
inoculation rate [15-18]. Alternatively, the epidemiology of malaria in a specific 
geographical area can be defined in terms of spleen enlargement and parasite rates among 
children [19]. More conveniently, the pattern of malaria transmission can be described as 
stable or unstable based on the fluctauation in the annual transmission. However, local 
epidemiologic features of malaria transmission may be drastically altered by 
environmental and/or social disturbances causing frequent epidemics. 
  
 
Figure. 1.1  The Global Distribution of Malaria Transmission Risk; 
Malaria is endemic in regions of 107 contries, mainly in sub-Saharan Africa. 
Source: The world malaria report 2005;  http://www.rbm.who.int/wmr2005/html/map1.htm.[20] 
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1.1.2. The biology of malaria. 
Malaria is a mosquito-borne disease that affects several vertebrate species including 
rodents, reptiles, birds and primates. The infection is transmitted by the bite of an 
infectious female Anopheles mosquito carrying a protozoan parasite of the genus 
Plasmodium. There are over 175 species of plasmodia currently recognised, many of 
these are known to cause malaria in non-human vertebrates [21]. However, humans 
malaria can solely be caused by four species of Plasmodium: P. vivax, P. ovale, P. 
malariae, and P. falciparum. Among these, P. falciparum is the most virulent and is 
responsible for almost all cases of severe disease and deaths. P. falciparum is the most 
common parasite in tropical Africa, and exists in all malaria endemic regions worldwide, 
while other species are variably distributed in different geographical locations [22, 23].  
More than four hundred species of Anopheles were identified, but only seventy of these 
are known to naturally transmit malaria to various vertebrates. [24, 25]. Human malaria 
parasites are transmitted by a few Anopheles species, of which, An. gambiae, An. 
arabiensis, and An. funestus are the most prevalent in Africa whereas other species such 
as An. albimanus, An. culicifacies, An. dirus, An. anthropophagus are found in other parts 
of the world [26].  
 
1.1.3. Plasmodium falciparum life-cycle. 
Plasmodium falciparum has a remarkably complex life cycle (Figure 1.2). The infection  
begins when sporozoites are released into the blood stream by a female Anopheles 
mosquito. The inoculated sporozoites circulate briefly before they invade the liver 
parenchymal cells where they undergo asexual replicative phase called exo-erythrocytic 
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schizogony. This liver stage of parasite lasts for approximately a week before releasing 
merozoites which invade red blood cells (RBCs).  
Erythrocyte invasion is crucial for parasite survival, it provides a rich source of nutrients 
in a niche (the parasitophorous) that is largely protected from host immune defense. The 
erythrocytic schizogony involves rapid successive mitotic divisions and generate 
thousands of merozoites which are released to re-invade new erythrocytes. It is this stage 
that is responsible for the acute clinical episodes of malaria. 
After a period of 7 to 15 days of asexual replicative cycles in RBCs, a small proportion of 
the merozoites undergo transformation into male and female gametocytes, the micro- and 
macro-gametocytes respectively. The half-life of the mature gametocyte in the blood is 
about 2.4 days during which it could be taken up by a feeding Anopheles mosquito.  A 
few minutes after ingestion by the mosquito, the micro-gametocytes exflagellate in the 
insect midgut, each  forms eight micro-gametes which move to fertilize the female 
macro-gametes. Eighteen to 24 hours after fertilization, the zygote elongates into an 
ookinete which traverses the membranes and the epithelial cells of the mid-gut and 
transforms into oocyst. The oocyst enlarges progressively as the nucleus divides 
repeatedly to form sporozoites. Mature sporozoites exit the oocyst to the coelomic cavity 
and migrate to salivary glands awaiting transfer to a new victim [27-29].  
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Fig 1.2. The life cycle of Plasmodium falciparum. 
Modified from the Center of Biologics Evaluation and Research, US, Food and Drug Administration: 
Accessed on the 3rd of June  2008. .www.fda.gov/Cber/blood/malaria071206sk.htm 
 
 
An infectious mosquito injects sporozoites into the blood stream of the human host, which then 
circulate with the blood to the liver. An exo-erythrocytic stage in the liver leads to release of 
merozoites into the blood stream. The merozoites invade the red blood cells and undergo an 
asexual replicative cycle  (the erythrocytic schizogony) to produce multiple merozoites capable of 
re-invading new red blood cells. Occasionally, erythrocytic trophozoites transform into 
gametocytes which are released into the blood stream and are eventually taken up by the 
mosquito, and then undergo the sexual stage of development (sporogenic cycle).  
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1.1.4. The malaria disease. 
1.1.4.1. Uncomplicated malaria. 
The clinical presentation of P. falciparum malaria is quite variable and generally mimics 
that of many other diseases caused by bacteria, rickettsia, and viruses. Initially malaria 
can have a gradual course of onset with non-specific symptoms including slight fever, 
anorexia, malaise and headache [30, 31]. The classical manifestations of the acute P. 
falciparum include fever with a feeling of coldness and chills followed by profuse 
sweating. Generalized symptoms such as backache, myalgia, aching joints, and 
gastrointestinal symptoms, i.e., anorexia, nausea, vomiting, abdominal pain, and mild 
diarrhea may also be found.  Unless the malaria infection in young children and non-
immuned individuals is diagnosed early and promptly treated, the condition may 
progressively deteriorate to a severe life-threatening disease with complex multi-system 
dysfunction [32].  
. 
1.1.4.2. Severe complications of malaria. 
Severe malaria (SM) is a complex multi-system disorder presenting with a considerably 
variable range of clinical manifestations [33]. In children and non-immune adults, many 
of severe complications of P. falciparum may occur in combination or as isolated 
manifestations. Such complications include cerebral malaria (CM), severe malarial 
anemia (SMA), respiratory distress, renal failure, and serious metabolic derangements 
including hypoglycemia and lactic acidemia. However, CM and SMA are the leading 
causes of malaria-related deaths in Africa. [31, 34-36]. 
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1.1.4.2.1. Cerebral Malaria (CM). 
Cerebral malaria (CM) is a syndrome of impaired consciousness associated with a P. 
falciparum malaria infection. Clinically, the term is loosely used to describe those at high 
risk of death due to SM. However, standardized criteria defining CM have been 
established by a panel of WHO experts, accordingly, the strict research definition of CM; 
is a condition of unarousable coma for more than 30 minutes after a generalized 
convulsion, confirmed by P. falciparum infection and exclusion of other causes of coma 
[37-41].      
In malaria endemic areas, CM accounts for up to 10% of all hospitalized cases of P. 
falciparum malaria, and for more than 80% of fatal cases. It occurs predominantly in 
patients with little or no parasite specific immunity, i.e., children under five years age in 
endemic areas or individuals coming from malaria-free areas.  
 
1.1.4.2.2. Severe malarial anemia (SMA). 
Severe malarial anemia (SMA) is defined as a haemoglobin concentration ≤ 50g/L (or a 
haematocrit ≤15%) in a patient with a P. falciparum parasitaemia with normocytic 
indices. The prevalence of SMA has increased during the last decade as a result of spread 
of chloroquine-resistant P. falciparum across the world [42-44]. SMA has a profound 
effects on communities in malaria endemic regions [45], anemia is associated with an 
increased risk of death [32], impaired cognitive and motor development [46-48],  retarded 
growth [49], diminished immune protection [50], and reduced physical work capacity 
[51].   
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1.2. Immunity to malaria. 
The immune system plays an important role in the host defense against infection with P. 
falciparum, and in limiting the extent of infection once it occurs.  Although most 
individuals living in malaria endemic areas are equally exposed to infectious bites of the 
Anopheles mosquitoes, a large proportion of the infected individuals either spontaneously 
resolve the infection, or remain asymptomatic i.e. harboring some parasitemia without 
significant clinical disease. A small proportion of infected individuals, mostly young 
children, develop clinical symptoms of malaria, and only less than 5% of these clinical 
cases proceed into severe life-threatening complications [52].  
The clinical pattern of malaria is markedly influenced by the age-dependent acquisition 
of anti-malaria immunity [53]. Different components of the immune system including 
both antibody-dependent and cell-mediated mechanisms operate at different stages of the 
parasite’s life cycle (figure 1.2) [54]. However, protective immunity to malaria takes 
years of exposure to infection before it develops significantly [55], and even with 
repeated infections, this immunity is rarely sterile, and is species-, variant-, strain-, and 
stage-specific [56, 57]. This inefficient and slow acquisition of anti-malaria immunity is 
attributed to the P. falciparum virulence and variability [54].  
 
1.2.1. The innate immune responses to malaria. 
Early interactions between sporozoites and host cells produce no significant systemic 
immune response and disease. Only merozoites are the stages that elicit strong immuno-
inflammatory responses.  Although not fully understood, several humoral components of 
innate immunity comprising the complement proteins [58], C-reactive proteins [59-61] 
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and mannose binding lectins [62-64] were implicated in protection from malaria. 
However, the principal innate effector mechanisms against malaria parasites are mediated 
by cellular components including monocytes-macrophages, natural killer cells, natural 
killer T cells and γ/δ T cells [65].  
The activation of monocytes-macrophages is one of the first events in the innate 
resistance to P. falciparum infection. Circulating monocytes and tissue resident 
macrophages in the liver, spleen, and other tissues are directly involved in phagocytosis 
and clearance of the infected red blood cells (iRBCs) [66, 67]. Malarial antigens such as 
the hemozoin pigment and/or the membrane-anchored glycosylphosphatidylinsitol, 
phagocytosed by the macrophages or acting through surface receptors, activate these cells 
to produce a series of pro-inflammatory mediators and cytokines. The inflammatory 
agents produced may have a direct anti-parasite activity or contribute to the activation of 
other effector immune mechanisms. However, these cells are also implicated in 
pathogenesis of severe malaria [68, 69].  
The natural killer (NK) cells interact with iRBCs and liberate pro-inflammatory 
cytokines, particularly IFN-γ [70-74]. In non-immune donors, NK cells can kill 
plasmodia-infected erythrocytes in the absence of opsonizing antibodies through direct 
cell-cell interaction [72-76]. Early production of IFN-γ by NK cells stimulated by IL-12 
during malaria infection is associated with a better prognosis of the disease [70, 72, 77]. 
Additionally, the interaction of NK with iRBCs induces production of the chemotactant 
IL-8 [78], suggesting a role for NK cells in recruitment and activation of other leukocytes 
during malaria infection.  
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Natural killer T cells (NKTs) are a specialized subset of lymphocytes that share 
properties of both T cells and natural killer (NK) cells. They differ from conventional αβ 
T cells in that;  they express the distinct NK.1.1 marker and possess a unique single 
invariant Vα14+ antigen receptor that recognizes lipids and glycolipids presented by 
CD1d molecules, rather than peptide-MHC complexes [79-81]. Experimental models 
have indicated a role for NKTs in conferring protection against murine malaria, and NKT 
cells were linked to malaria-associated splenomegaly and expansion of the splenic B cell 
pool forming the parasite-specific antibody. [82-85].  
The gamma/delta (γ/δ) T cells constitute a minor subset of T lymphocytes characterized 
by an antigen receptor formed of γ and δ chains rather than the common α and β chains 
that make up the antigen receptors on the conventional T cells [86]. Peripheral γ/δ T cells 
are strongly up-regulated during malaria, and they respond to malaria antigens by 
proliferation and lymphokine production [87-89]. Activated γ/δ T cells but not α/β T cells 
from malaria-naïve donors were shown to inhibit parasite replication in eryhrocytes in 
vitro, indicating an important innate protective a role against malaria [90].  
 
1.1.1. Adaptive immune responses to malaria. 
1.1.1.1. Anti-sporozoite immunity. 
Protective immunity against malaria can be induced in animal models and humans 
following immunization with irradiated sporozoites.[91-93]. Although it confers 
complete resistance to subsequent sporozoite challenges, such immunity is stage-specific 
and does not resist challenges with blood stage Plasmodium. Anti-sporozoite antibodies 
are the principal effectors that promote phagocytosis and block hepatocytes invasion [94]. 
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Such antibodies are mainly directed against the most abundant sporozoite surface 
proteins, the circumsporozoite protein (CSP) and the thrombospondin related adhesive 
protein (TRAP) as well as several other sporozoite and liver stage antigens. Most adults 
in malarious areas were found to possess high titer of antibodies to the CSP of P. 
falciparum [95], and the immune sera obtained from sporozoite-immunized human 
volunteers, and naturally infected individuals, were found to block the invasion of P. 
falciparum sporozoite into hepatocytes [96].  
 
1.1.1.2. Immunity to liver stages of malaria parasite. 
Several cellular mechanisms are implicated in generating protective immunity against the 
liver stages of Plasmodium [97-101]. T cells were shown to be involved in the generation 
of protective immunity in rodents immunized with irradiated sporozoites.[102, 103], and 
the passive transfer of CD8+ T cells and CD4+ T cells clones derived from sporozoite 
immunized mice was found to confer protection [104-107]. Cytotoxic T lymphocyte 
response to CS proteins was observed in field studies and believed to protect against pre-
erythrocytic stages of malaria [108].  
  
1.1.1.3. Immunity to blood stages of malaria parasite. 
As previously noted, invasion of red cells is the key step in malaria infection and is the 
cause of clinical disease, hence erythrocytic stages of P. falciparum are likely to be the 
most important targets for protective immune responses. Protective immunity against 
erythrocytic stages involves both antibody-dependent and cell-mediated immunity [109, 
110].  
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1.1.1.3.1. Antibody-mediated immunity to blood stages of P. falciparum. 
Passive transfer of anti-Plasmodium specific antibodies to non-immune mice, and 
treatment of P. falciparum infected patients with immunoglobulins extracted from 
naturally immune individuals, result in reduction of parasitemia and clinical symptoms 
[111-115]. Moreover, studies in gene-targeted, and B-cell deficient mice demonstrated 
that B cells are essential for the resolution of blood stage infection of murine malaria, 
thus, protection from malaria was thought to be mainly an antibody-mediated type of 
response [116, 117].   
In people living in malaria endemic areas, exposure to repeated infections with different 
variants of P. falciparum induces production of polyclonal antibodies, predominantly 
IgM, IgG isotypes [118-122], and the acquired protective immunity to malaria correlates 
with the individual age and the level of antibodies against the asexual blood stage 
antigens of the parasite [14, 123-125]. Such epidemiologic observations explain the slow 
acquisition of protective immunity to malaria during the first years of life in parallel with 
the expansion of the antibody repertoire against variant surface antigens (VSA). 
Accordingly, a clinical episode in a child living in a malaria endemic area represents an 
infection with a parasite expressing VSA not recognized by the existing repertoire of 
antibodies.[121, 126-129]. 
Early studies have clearly demonstrated the predominance of immunoglobulin-G (IgG) in 
resolution of the blood stage infection, and several antibody-mediated mechanisms of 
parasite growth inhibition and killing have clearly been elucidated [130-132]. IgG 
antibodies directed against merozoite surface proteins enhance various effector 
mechanisms including; opsonization,  phagocytosis [132-134], complement-mediated 
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damage of merozoites [135], blockage of RBC invasion [136, 137], and antibody-
dependent cellular inhibition (ADCI) of parasite growth [132, 138].  
 
1.1.1.3.2. Cell-mediated immunity to blood stages of P. falciparum. 
The first observations showing the importance of T lymphocytes in recovery from 
malaria infections were made by Brown and co-workers in their experiment with 
thymectomized rats [139]. Later, it was shown that B cell deficient mice can be 
immunized by natural infection with Plasmodium, and that adoptive transfer of CD4+ T-
cell clones could confer protection against malaria [140-142]. However, because 
erythrocytes do not express MHC molecules, it seems unlikely that T cells could have a 
direct cytotoxic effects on infected erthrocytes. Alternatively, it was suggested that T 
cells respond to malaria antigens by cytokines secretion. In consistence with this view, it 
was shown that stimulation of T cells by malarial antigens presented by antigen 
presenting cells (APCs) results in release of various cytokines, and experiments with 
gene-knocked-out mice, have shown that, immune responses to blood stages of  
Plasmodium are mostly mediated by IFN-γ-secreting T lymphocytes [99, 116, 143].  
Both Th1 and Th2 types of CD4+ T cells were implicated in malaria protection and 
pathogenesis in mice. It has been shown that; CD4+  T cells of the Th1 type which 
produce IL-2 and IFN-γ, are important during the acute phase of murine infection with 
Plasmodium chabaudi chabaudi AS whereas Th2 type of these cells is required during 
later phases to provide help to B-cells through IL-4 secretion.[144, 145]. The secretion of  
IFN-γ  by T lymphocytes is believed to induce the cytophilic IgG blood-stage-specific 
antibodies and assist in antibody-dependent cellular inhibitory mechanisms [138]. 
Additionally, the CD4+ Th1 cells can kill parasites in the absence of antibodies through 
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monocyte-macrophage activation with the subsequent generation of  reactive oxygen and 
nitrogen intermediates [146, 147]. In humans, CD4+ T cells were shown to inhibit 
parasite growth in vitro [148], and the production of IFN-γ by CD4+ T cells in response 
to specific erythrocytic antigens was associated with protection from malaria in field 
studies in Africa [149, 150].  In the other hand, the CD8+ T cells seem to play no 
significant role in protection against blood stage malaria in mice. Consistent with this, 
depletion of CD8+ T cells during primary blood stage infection did not diminish the 
ability of the mice to resolve infection. [151, 152]. However, experiments with mice 
treated with anti-CD8+ mAb showed significantly higher levels of parasitemia than 
untreated control mice, suggesting some role for CD8+ cells in containing the blood 
stages of murine malaria [153]. However, in humans, CD8+ T cells may have indirect 
regulatory effects on the immune responses to blood stage infection during acute malaria 
[154, 155]. 
 
1.2.    The immuno-pathogenesis of severe malaria. 
Malaria is a complicated syndrome and the clinical outcome of infection with P. 
falciparum is determined by several factors. Such factors include the intensity of parasite 
transmission, the parasite virulence, together with numerous host genetic, nutritional, and 
immunological characteristics [35, 52, 156-165]. However, the mechanisms leading to 
severe life-threatening complications of malaria are not fully understood [52, 166]. 
 
1.2.1. The pathogenesis of cerebral malaria. 
The mechanisms underlying the pathogenesis of CM remain controversial, and several 
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hypotheses were set to explain the cause of this deadly syndrome [167-170]. The 
mechanical (sequestration) hypothesis assumes that P. falciparum-parasitized 
erythrocytes bind to the post capillary venules, causing obstruction of blood flow,  and 
thereby decrease tissue perfusion and impair wastes disposal leading to brain pathology 
[169, 171]. Histological examination of brain sections from fatal cases of CM revealed 
sequestration of iRBCs in multiple organs and tissues [172]. However, due to lack of 
sequestration in some patients with cerebral symptoms, and the fact that most patients 
with CM fully recover without evidence of ischaemic damage, the mechanical hypothesis 
cannot adequately explain the cause of CM. Alternatively, it has been suggested that; 
malaria toxins bind to and stimulate monocytes to secrete pro-inflammatory cytokines 
[156, 173, 174]. Although, the cytokines themselves are not harmful, they may induce 
production of nitric oxide (NO) [175-178] which diffuses through the blood-brain barrier 
and interferes with the synaptic function as do general anesthetics, leading to a state of 
reduced consciousness [179]. Several malarial antigens, such as the membrane-anchored 
glycosylphosphatidylinositol (GPI) and the by-product of parasite metabolism the 
hemozoin, can cause cytokines release from various host immune cells [180]. The 
released cytokines up-regulate the expression of various endothelial adhesion receptors 
such as ICAM-1, PECAM-1/CD31, and thus enhance cytoadherence of iRBCs and 
sequestartion [179, 181]. Sequestered parasites in the brain vasculature may locally 
release more toxins and induce the production of inflammatory mediators that disrupt the 
brain function and metabolism leading to the CM. 
Most recently van der Heyde et al., suggested a unified hypothesis to explain the etiology 
of CM [170]. They attributed CM to a combination of parasite-host specific interactions 
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that promote iRBCs adhesion and sequestration in the microvasculature of various organs 
and tissues causing the induction and release of cytokines and several other bioactive 
molecules which trigger excessive immuno-inflammatory responses that disturb the 
homeostasis [170, 182].  
 
1.2.2. The pathogenesis of severe malaria anemia. 
Severe malaria anemia (SMA) is the most common complication of malaria in 
holoendemic areas and contributes substantially to the mortality and morbidity from this 
disease. The pathogenesis of SMA is multi-factorial, and is only partially understood. It 
involves both accelerated clearance of erythrocytes from the circulation and suppression 
of hematopoeisis [164, 183, 184]. During acute P. falciparum infections, parasite 
replication results in an increased rate of RBCs destruction, but this cannot solely account 
for the marked reduction in hemoglobin levels observed in patients with SMA. In 
contrast, children with SMA were shown to have lower peripheral parasite densities than 
parasitemic children without anemia [185, 186] Moreover, an increased rate of clearance 
of uninfected erythrocytes associated with low reticulocyte levels was also observed in 
these patients suggesting involvement of inflammatory processes in the pathogenesis of 
SMA [187-194]. The analysis of microarrays profile gene expression in a murine model 
of malaria has shown repression of erythroid-associated transcripts during plasmodial 
infection, providing additional confirmation for a role of the inflammatory mediators in 
the etiology of SMA  [195]. High circulating levels of the proinflammatory cytokines 
TNF-α and IFN-γ and low levels of the anti-inflammatory IL-10 were associated with 
SMA, supporting the hypothesis that specific cytokine disbalance may lead to SMA [196-
198]. Moreover, impairment of IL-12 response was shown to contribute to the 
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development of SMA [199, 200], and low plasma levels of IL-12 have repeatedly been 
reported in patients with SMA [201-204]. Macrophage migration inhibitory factor (MIF) 
has also been suggested to play an important role in the pathogenesis of malarial anemia 
[68], and elevated plasma MIF concentrations were associated with suppression of 
erythropoiesis and enhanced severity of anemia in murine models [68, 69]. However, 
MIF production by monocytes in children with acute malaria was shown to decline 
progressively with increasing anemia severity (167). 
 
1.2.3. The role of cytokines in immuno-pathogenesis of  malaria. 
The  importance of cytokines in protection from and pathogenesis of infectious diseases 
is well established, and altered production of cytokines is widely held as a mechanism 
responsible for a variety of immuno-inflammatory diseases [33, 205-207].  
The first speculations that malaria parasites elicit a systemic inflammatory response that 
causes disease appeared early in 1940s [208, 209]. The striking similarities between the 
patho-physiology of acute P. falciparum malaria and septic diseases together with the 
detection of elevated levels of circulating inflammatory mediators in animals receiving 
endotoxin and in animals infected with malaria parasites led to the notion that; 
macrophage derived factors may be responsible, at least in part, for the pathology 
observed in malaria [164]. Pro-inflammatory cytokines are now recognized causal 
mediators of malaria fever and low levels of anti-inflammatory cytokines such as IL-10 
and transforming growth  (TGF-β) and/or increased ratios of pro-inflammatory to anti-
inflammatory factor-β cytokines have repeatedly been associated with increased risk of 
high fever and severe malaria  [196, 198, 202, 210-213] 
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1.2.3.1. Interferon- γ (IFN-γ). 
There is a growing consensus that IFN-γ plays a central role in protection from malaria 
[71, 72, 147, 149, 173, 214-216].  IFN-γ induces the effector mechanisms essential for 
control of both pre-erythrocytic and blood-stage malaria infections [99]. Treatment of 
mice with exogenous IFN-γ delayed the onset of parasitemia, decreased the parasitemia 
and increased mice survival [173, 216]. Conversely, treatment of Plasmodia-infected 
mice with neutralizing monoclonal antibodies to IFN-γ exacerbated the course of 
infection [217, 218]. Moreover, studies with IFN-γ knocked-out mice confirmed the 
critical role of IFN-γ in the protective immunity to malaria [219, 220]. In clinical studies, 
elevated levels of serum IFN-γ were found in patients with acute malaria [221-226], and 
individuals heterozygotic for an IFN-γR1 polymorphism had a lower incidence of CM 
and death in Gambia [227].  
 
1.2.3.2. Tumor necrosis factor α (TNF-α). 
Tumor necrosis factor (TNF-α) plays pivotal roles in many inflammatory processes, and 
is implicated in pathogenesis of various acute and chronic illnesses, encompassing  both 
infectious and non-infectious diseases [164, 228-230]. Ample evidence demonstrated the 
importance of TNF-α in the immune response to malaria infection [33, 175, 222, 231-
238], and several antigens of P. falciparum blood stage parasites as well as hemozoin 
granules induced TNF-α production in peripheral blood monocytes in vitro. The 
glycosylphosphatidylinositol (GPI) is the major malaria toxin responsible for the TNF-α 
release and induction of fever [180]. Raised levels of plasma TNF-α were found in the 
general population during the malaria transmission season, and were associated with 
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acute and severe malaria [233, 239-245]. TNF-α upregulates the ligands that bind iRBCs 
and promotes sequestration in the brain capillaries, a process that is central to 
pathogenesis of CM [246, 247]. In addition, hyperlactaemia [248], hypoglycaemia [222] 
and fever [241] in malaria patients have all been correlated with elevated levels of serum 
TNF-α. However, the failure of TNF-α neutralizing agents to decrease the incidence of 
clinical CM and the disappointing outcome of trials with pentoxifylline and steroid 
therapy for CM raise doubts about the role of TNF-α in the pathogenesis of CM [249, 
250].  Moreover, there is an emerging view claiming that lymphotoxin-α, and not TNF-α, 
may be the principal mediator of human CM [238, 251]. 
 
1.2.3.3. Lymphotoxin (LT-α). 
There is evidence indicating a distinctive role for LT α in malaria [238, 251-253]. Like 
TNF-α , LT-α has been detected in human malarial serum, and was shown to induce high 
levels of IL-6 and causes hypoglycemia in a mouse model [253]. LT-α but not TNF-α 
was found necessary for IFN-γ production during malaria infection [251].  
 
1.2.3.4. Interleukin-1 (IL-1). 
Interleukin-1 (IL-1) is a family of pro-inflammatory cytokines which comprises IL-1α, 
IL-1β, and the IL-1 Receptor antagonist (IL-1RA) [254]. Production of IL-1 by 
macrophages, monocytes and dendritic cells enhances T cell-dependent antibody 
production and increases the expression of adhesion molecules on endothelial cells to 
enable transmigration of leukocytes to sites of infection [254-256]. Both IL-1α and IL-1β 
are potent pyrogens that are implicated in the causation of malaria fever. Administration 
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of recombinant IL-1 reduced parasitemia and protected mice from lethal cerebral malaria, 
and elevated serum levels of IL-1 were found in malaria patients in a holoendemic area 
[257]. 
 
1.2.3.5. Interleukin-4 (IL-4). 
Interleukin-4 is a pleiotropic cytokine that plays a critical role in both the proliferation of 
lymphocytes and regulation of lymphokine production [160, 258]. IL-4 was shown to 
inhibit Th1 cell differentiation and to induce a reversion of developing Th1 cells to the 
Th2 lineage through inhibition of IFN-γ [259]. Early addition of IL-4 to cultures of 
human CD4+ T cells was shown to impair IL-2 and IFN-γ synthesis by these cells 
suggesting an immune-suppressive effect [260]. However, addition of exogenous IL-4 to 
in vitro cultures is required for the differentiation of naive CD4+ T cells into IL-4-
secreting Th2 cells [261-264], indicating a critical  role in the development of Th2-type 
immune responses and possibly in the regulation of immunoglobulin switching to IgE 
and IgG isotypes [265-267]. Thus, IL-4-producing T cells were suggested to induce the 
production of malaria specific IgG and elevated levels of IL-4 were detected in 
parasitemic individuals living in malaria endemic areas [257]. It has also been shown that; 
IL-4 receptor expression on CD8+ T cells is required for the development of protective 
memory responses against liver stages of malaria parasites [268].  
 
1.2.3.6. Interleukin-6 (IL-6). 
Interleukin-6 is one of the most important mediators of fever and is required for the 
activation, proliferation, and survival of T cells and dendritic cells [269-275]. 
In malaria, IL-6 was shown to mediate the anti-parasitic activity of IL-1 on the liver 
 34 
 
stages of malaria parasite [276], and patients with malaria fever were found to have 
elevated serum levels of IL-6 [240, 245, 277-279]. Interestingly, higher serum levels of 
IL-6 were found in severe malaria than in uncomplicated malaria patients [242, 280, 281] 
and raised levels of this cytokine were associated with hyperparasitemia, jaundice, and 
shock in Vietnamese patients [282]. 
 
1.2.3.7. Interleukin-8 (IL-8) and chemokines. 
The role of IL-8 in malaria pathogenesis is not clearly understood and conflicting results 
were reported [245, 283-285]. However, elevated serum levels of IL-8 have been noted 
during acute malarial attack [283, 284]. 
 
1.2.3.8. Interleukin-10 (IL-10). 
Interleukin-10 (IL-10) was initially identifed as a cytokine synthesis inhibitory factor 
(CSIF) produced by mouse Th2 cells and inhibits Th1 cells cytokine production [286]. It 
is primarily produced by cells of the monocyte/macrophage lineage and to a lesser extent 
by activated T and B cells [287-289]. IL-10 has extensively diverse effects mediated 
through specific cell surface receptor complex (IL-10Rα and IL-10Rβ) expressed on most 
hemopoietic cell types. It acts as a suppressor of immune responses, principally through 
down-regulating the expression  of the MHC class II, the costimulatory molecules and 
cytokines genes in the antigen presenting cells [289-292]. For, example, IL-10 is known 
to inhibit the secretion of IFN-γ by Th1 cells [286, 293], and of TNF-α  and MIF by 
monocytes and macrophages [290, 294], and it modifies the expression of chemokine 
receptors [295]. In various experimental models, induction or administration of IL-10 
suppressed the antigen-specific T-cell proliferation and contributed to the establishment 
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of persistent infection by a number of pathogens including HIV [296] Mycobacterium 
tuberculosis [297], Listeria monocytogenes [298], Trypanosoma cruzi [299]. However, 
although generally precieved as an anti-inflammatory cytokine, IL-10 could have quite 
opposite effects on some specific models [300, 301]. For instance, IL-10 was found to 
stimulate the expression of MHC-II molecules and the production of immunoglobulins in 
B cells [302], and to augment the proliferation and cytotoxicity of NK cells when 
combined with IL-18 [303]. 
Increasing evidence demonstrates the role of IL-10 in malaria protection and 
pathogenesis [210, 226, 245, 304-307]. Murine and in vitro studies have demonstrated 
IL-10’s ability to inhibit TNF-α production in response to malarial antigens [221], and 
high levels early during malaria infection were found to inhbit Th1 type of immune 
responses in both mice and humans. These raised levels were also associated with less 
effective clearance of Plasmodial parasites and subsequently the development of severe 
malarial complications, particularly SMA [210, 245, 305, 308, 309]. In contrast, IL-10 
has been suggested to play a protective role against experimental cerebral malaria [307, 
310], and clinical studies associated insufficient IL-10 with acute and severe malaria 
[196, 198, 282]. Moreover, it was demonstrated that, in individuals with SMA, plasma 
levels of TNF-α tend to exceed those of IL-10, and low ratios of IL-10:TNF were found 
to be a risk factor for both CM and SMA, whereas higher ratios were more frequent 
among hyperparasitemic individuals [311]. Interestingly, low circulating IL-10 associated 
with high pro-inflammatory cytokines levels was noted in comatose patients with CM 
[282], suggesting protective effect for IL-10 against SM. Therefore, while it may be 
detrimental by decreasing cellular immune responses to parasite,  IL-10 may equally be 
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beneficial in preventing excessive inflammation that underlies the SM. It is currently  
assumed that not only the levels but also timely production of IL-10 is crucial for 
controlling the parasite growth and replication as well as for preventing excessive 
inflammatory responses to P. falciparum.  
 
1.2.3.9. Interleukin-12 (IL-12) . 
Interleukin-12 plays an important regulatory role in both the cell-mediated [201-203, 213, 
312-315] and antibody-mediated [316] immune responses to malaria. IL-12 has been 
inversely associated with disease severity in experimental and human malaria. 
Administration of IL-12 decreased mortality and reduced parasitemia in mice through a 
mechanism which appears to be critically dependent on IFN-γ [201, 203, 315, 317, 318]  
 
1.2.3.10. Interleukin-18 (IL-18). 
Elevated levels of IL-18  have been found in adult patients with uncomplicated P. 
falciparum malaria, and these levels were found to decrease with recovery from disease 
[319]. Higher levels of IL-18 were found in children with mild malaria than in children 
with a severe malaria, suggesting a protective effect against severe malaria.[202, 320]). 
Impaired IL-18 response was shown to contribute to the development of SMA in areas of 
holoendemicity for malaria [204]. 
 
1.2.3.11. Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF).  
Granulocyte-macrophage colony stimulating factor (GM-CSF) gene-knocked out mice 
were found to be more susceptible to infection with P. chabaudi AS than wild-type mice 
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[321], indicating a protective role against murine malaria. GM-CSF was shown to act 
synergistically with TNF-α in priming neutrophils for enhanced phagocytosis and killing 
of asexual stages of P. falciparum and to up-regulate expression of cytokines, 
complement proteins and Fc receptors [322]. Incorporation of a plasmid encoding murine 
GM-CSF in a DNA vaccine against the CSP of P. yoelii enhanced the efficacy of the 
vaccine [323]. However, elevated serum levels of GM-CSF were recorded in severe 
human P. falciparum malaria [223, 324]. 
 
1.2.3.12. Transforming Growth Factor-β ( TGF-β). 
Transforming growth factor-β (TGF-β) plays a key role in limiting malaria pathology, 
and reduced levels of TGF-β were  associated with severe malaria [211, 325, 326]. 
Increased mortality was observed among IL-10−/− mice when infected with the normally 
non lethal P. chabaudi [265], and treatment of P. berghei infected mice with anti-TGF-β 
antibodies increased the parasite virulence, suggesting a protective effect for TGF-β 
against severe disease [326, 327]. Conversely, treatment of these mice with recombinant 
TGF-β resulted in upregulation of IL-10 and down-regulation of TNF-α and extended 
survival time [326, 327]. However, induction, or administration of TGF-β during early, 
acute blood-stage infection suppresses protective proinflammatory cytokine responses, 
leading to unrestrained parasite proliferation and increased disease severity [328-330]. 
 
1.2.4.  Cytokine gene polymorphisms and malaria protection and pathogenesis. 
The search for genetic variation associated with disease is an exciting area of medical 
investigations that has rapidly expanded during the last decades and contributed to better 
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understanding of mechanisms of protection and pathogenesis of many diseases. Genetic 
markers in cytokine genes are becoming widely used in studies of immune-mediated 
disease, and it is becoming apparent that inherited differences in cytokine genes 
contribute to phenotypic variations, risks of disease and responses to the environmental 
stimuli including infectious challenges [331-340].  
 Interindividual differences in cytokine profiles appear to be due mainly to allelic 
polymorphism within regulatory regions of the cytokine genes. The biallelic mutations, 
the single nucleotide polymorphisms (SNP), are the most common source of variations in 
the human genome [333].  
Analyses of interindividual differences and genetic polymorphisms in association with  
malaria protection and pathogenesis may provide insight into new strategies for fighting 
malaria. [341, 342]. Examples of the clearly demonstrated associations of malaria risk 
with cytokine gene polymorphisms include two substitutions at the positions -308 [343, 
344] and  -376 upstream of the transcriptional start of the TNF-α gene  [244]. Both 
polymorphisms were identified as independent risk factors for cerebral malaria in African 
populations[243, 244, 345].  A long list of reports associating certain SNPs in different 
cytokines genes with malaria is currently available. However, the following discussion is 
confined to polymorphisms in IL-10 which is investigated in the current study. 
 
1.2.4.1. Interleukin-10 gene polymorphisms. 
The IL-10 gene promoter is highly polymorphic, it contains two informative 
microsatellites, IL10.G and IL10.R and eleven single nucleotide polymorphisms (SNPs), 
of which the three proximal ones located at positions (-1082 G/A [rs 1800896], -819 C/T  
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[rs 5289772] and -592 C/T [rs5289771]) are the most frequent points of mutations [337, 
346-355]. Differences in the genotypes and allele frequencies in these SNPs were 
observed  between different populations. These differences may influence the outcomes 
of certain infections in different populations [356, 357] Interestingly, the -1082G allele 
was associated with higher production of IL-10 compared to the A allele both in vitro and 
in vivo [347, 358, 359], whereas polymorphisms at positions -819 and -592 appear to 
have no influence on IL-10 production [347]. 
Several studies have demonstrated the relevance of these SNPs to susceptibility and/or 
severity of a number of diseases including the inflammatory bowel disease [360-362], 
psoriasis [363-365], primary Sjogren’s syndrome [366], rheumatoid arthritis [358, 367], 
myocardial infarction [368], coeliac disease [369] and systemic lupus erythematosus 
[353, 370]. Similarly, several infectious diseases were associated with certain alleles in 
these SNPs.  
Genetic predisposition to high IL-10 expression has been reported to be associated with a 
higher rate of mortality in meningococcal disease [334, 371]. Chronically infected 
hepatitis C patients who are genetically predisposed to high IL-10 production were 
reportedly less likely to benefit from IFN-α therapy [372]. Moreover, associations have 
been reported between IL-10 polymorphisms and Epstein– Barr virus infection [373], 
leprosy [374] severe malaria [375],  and recurrence of hepatitis C in liver transplant 
patients [376]. Of particular significance, is the A/G transition at position -1082 which 
has been associated with rheumatoid arthritis [367], systemic lupus erythematosus [370], 
psoriasis [365], coeliac disease [369], graft-versus host disease [377], and the severity of 
P. falciparum malaria in African children [375]. 
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1.3. The Present Study: 
This thesis is based primarily on results obtained in two studies which will be referred to 
as (Study I and II). The studies were carried out as a part of the severe malaria project in 
the Malaria Research Laboratory, Department of Biochemistry, Faculty of Medicine, 
University of Khartoum, Sudan,  in collaboration with the Department of Immunology, 
Wenner-Gren Institute, Stockholm University, Sweden. Manuscripts of intended 
publications originating from these studies, together with reports of other relevant work 
to which the author contributed during the study period are annexed to the thesis.  
 
1.4. Rationale. 
Study I. 
Natural antibody-mediated immune responses are essential for acquisition of protective 
immunity against malaria infection and disease in endemic areas [378-380]. Passive 
transfer of malaria specific immunoglobulins has been shown to reduce parasitemia and 
to improve the clinical condition of malaria patients [381, 382]. Early studies have clearly 
demonstrated the predominance of immunoglobulin-G (IgG) in resolution of the blood 
stage infection, and several antibody-mediated mechanisms of parasite growth inhibition 
and killing have clearly been elucidated [130-132]. Identification of  potential targets and 
mechanisms of antibody-mediated protective immunity is central for rational vaccine 
development [383, 384] 
Generally, natural IgG responses in human comprise four distinct antibody subclasses 
with varying structural and functional properties. Previous studies which mostly 
investigated antibody response to either individual or limited panels of malarial antigens, 
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have somehow associated levels of certain subclasses of IgG antibodies with some 
parameters of protection from malaria as reviewed by Garraud et al.[385]. However, only 
a few field studies have investigated the role of IgG subclasses in protection against SM. 
For example, low levels of serum IgG3 against crude extract of P. falciparum blood-stage 
are associated with poor prognosis of SM, and increased IgG3 is associated with reduced 
risk of malaria attack in Senegal [308, 386]. In a prospective case-control study of 
Kenyan children, the mean levels of IgG class and subclass antibodies against crude 
P. falciparum antigen were comparable between children who developed SM and those 
who remained healthy for two consecutive transmission seasons [387].  However, in the 
same study, high levels of IgG1 in relation to IgG2 and IgG4 antibodies were  associated 
with protection, whereas high levels of IgG2 in relation to IgG1 and IgG3 were  
associated with risk of SM [387]. In contrast, levels of IgG subclasses to P. falciparum 
were found to be the same in protected and non protected subjects in Madagascar [388]. 
Interestingly, among IgG class and subclass antibodies directed against four vaccine 
candidate antigens; the apical membrane antigen-1 (AMA-1), the merozoite surface 
protein-119 (MSP-119), MSP-3, and  the glutamate-rich protein (GLURP), only levels of 
total IgG, IgG3 and IgG4 antibodies against GLURP and IgG1 antibodies against AMA1 
were associated with reduced risk of malaria incidence in Burkina Faso [389]. In addition 
to the intrinsic properties of antigens, the association between IgG antibody levels and 
protection from malaria may vary with the age and the genetic constitution of the host, as 
well as the parasite density and strain. Thus, in spite of the convincing evidence for an 
important role of the cytophilic IgG1 and IgG3 in parasite killing, the role of IgG 
antibody subclasses in protection from SM complications is not clearly understood. In 
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particular, the relevance of the quantitative variation of these antibodies and protection 
from SM in areas of seasonal parasite transmission remains to be clearly defined. Here, 
we undertook analyses of levels of circulating anti-malarial IgG subclasses directed 
against crude malaria antigen in order to determine whether particular IgG subclasses are 
associated with protection from SM, and to find out how such associations might be 
influenced by the host age, parasite density and multiplicity of infection (MOI). 
 
Study II. 
Interleukin-10 (IL-10) is an important immuno-suppressive cytokine produced by several 
cell types including macrophages, B and T lymphocytes and dendritic cells. The main 
biological function of IL-10 seems to be the restriction of inflammatory responses and the 
regulation of proliferation and differentiation of immune cells [300, 390].  
Interleukin-10 has repetitively been associated in various ways with severe complications 
of P. falciparum malaria. For example, animal models, although not perfectly 
reproducing the human disease, have provided evidence for an important role of IL-10 in 
the pathogenesis of CM [163, 251, 391]. IL-10, principally from splenic T cells, was 
shown to play a crucial role in protection of C57BL/6 mice against the neurological 
syndrome associated with P. berghei ANKA infection [310]. This has further been 
substantiated by the demonstration of IL-10’s ability to inhibit IFN-γ production and to 
protect against CM [307], and by the observation of enhanced malaria disease of P. 
chabaudi chabaudi infection in IL-10 knocked-out mice [307, 392, 393]. Therefore, 
inadequate production or defective respond to IL-10 were suggested as possible 
pathogenic mechanisms of severe malaria [196, 198, 282, 304].  However, the role of 
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circulating levels of IL-10 in protection from or pathogenesis of human malaria is not 
well understood. Several reports have associated elevated circulating levels of IL-10 with 
acute malaria [210, 226, 394], severe malarial anemia (SMA) [212], and CM [210, 245]. 
Moreover, high IL-10 levels during the early phase of infection were associated with less 
effective clearance of parasites and hyperparasitemia [305, 309]. Conversely, other 
authors have associated low levels of IL-10 with CM in deeply comatose patients [282], 
as well as with SMA [196, 395].   
Quantitative differences in IL-10 production may partially be attributed to heritable 
genetic factors[334, 396]. Several nucleotide polymorphisms (SNPs) identified in the IL-
10 gene promoter were associated with differences in rates of the cytokine  production 
[348]. The relevance of these SNPs to susceptibility to and/or severity of inflammatory 
and infectious diseases has been demonstrated [373-375]. For example, the A/G 
transition at position -1082 (rs 1800896) has been associated with either protection 
against or enhanced severity of several inflammatory and infectious diseases including 
Epstein–Barr virus infection [373], inflammatory bowel disease and ulcerative colitis 
[397], Juvenile rheumatoid arthritis [358] and chronic hepatitis C virus infection [372].  
Here, I investigated whether a particular allele or genotype at position -1082 is associated 
with protection from or susceptibility to SM malaria, and whether this is related to the 
circulating levels of IL-10 in different forms of clinical malaria among Sudanese children 
living in areas of unstable seasonal malaria transmission.  
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1.5. The General  Objectives: 
The overall objective of these studies was to investigate the role of the anti-malaria 
immunoglobulin-G subclasses and interleukin-10 in the immune-pathogenesis of malaria.  
 
1.5.1. The specific objectives 
1.5.1.1.  Study I. 
1. To measure circulating levels of anti-malarial immunoglobulin-G (IgG) isotypes 
in order to examine how these levels relate to malaria protection and 
pathogenesis. 
2. To determine the multiplicity of infection (MOI) by Plasmodium falciparum in 
patients with severe and uncomplicated malaria, and to assess the effect of MOI 
in the acquisition of the antibody mediated immunity to malaria. 
 
1.5.1.2. Study II. 
1. To measure the circulating levels of IL-10 in order to determine if these levels 
correlate with a particular genetic allele, and how they affect the outcome of 
malaria infection. 
2. To determine the genotypes and the allele frequencies of the single nucleotide 
polymorphism (SNP) at position -1082 [rs 1800896], in order to find out how 
they relate to protection from severe malaria. 
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Chapter Two 
  
Material and Methods 
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2.   Material and Methods: 
2.1. The study area and population.  
These studies were carried out over a period from September to December 2003, in El-
Gedarif Hospital and during the same period in 2006 in El-Obied Teaching Hospital. El-
Gedarif town (350 to 400 thousand inhabitants) is situated on the Sudanese Savanna, at 
an altitude of about 600 m above sea level, and is located 350 km southeast of the capital, 
Khartoum. The epidemiology of febrile uncomplicated malaria episodes in the area has 
been reported before [398]. Malaria in this area is highly seasonal, and follows the annual 
June-October rains; the seasonal incidence of malaria varies considerably from year to 
year [399]. Anopheles arabiensis is the sole malaria vector in the area. The entomological 
inoculation rate in Gedarif was found too low and difficult to measure by conventional 
methods in the surrounding villages [400].  
 
El-Obied, the capital of the state of North Kordofan, is 400 km south-west of Khartoum. 
North Kordofan State lies in arid semi-desert area, and has a population of around 2.6 
million, mainly sedentary farmers and nomad livestock breeders. The rainy season 
extends from June to mid-September with an annual rainfall of less than 400 millimetres, 
allowing grazing and seasonal rain-fed agriculture. The malaria epidemiology and 
clinical features in this area have not been investigated and little information is available 
about the disease prevalence and incidence. 
 
The patients attending the out-patient clinic of El-Gedarif Hospital and the Paediatric 
Unit of El-Obied Teaching Hospital during the mentioned periods were carefully 
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screened for the signs of malaria. A patient was defined to have malaria if he/she 
complained of fever, had body temperature exceeding 37.5oC with asexual malaria 
parasites detected in the blood. Patients who met the criteria for severe and 
uncomplicated malaria as described by the World Health Organisation (WHO) [24] were 
selected for study. Patients classified with cerebral malaria were in unarousable coma 
which persisted for at least 30 minutes after a seizure while patients with severe malarial 
anaemia had normocytic anemia with haematocrit <15% or haemoglobin <5 g/dl in the 
presence of microscopically detectable parasitaemia. Uncomplicated malaria cases were 
described as having a positive blood smear, fever, headache, and no signs of severe 
manifestation. All patients were promptly treated free of charge according to the hospital 
treatment protocols.  
 
The study was approved by the research committee of the Faculty of Medicine, 
University of Khartoum, and the National Research Directorate of the Sudan's Federal 
Ministry of Health. Informed consents were obtained from the patient and/or their  
guardian before enrollment. Unrestricted immediate access to health care was granted for 
all patients regardless of their acceptance or refusal of enrolment in the study. 
Comprehensive demographic and clinical data were recorded in the study questionnaire. 
All participants were subjected to a series of clinical investigations including 
haemoglobin (Hb%), blood glucose level, and a complete haemogram. Thin and thick 
blood smears were prepared to investigate parasitemia, species and density.  Samples of 
venous blood were collected in EDTA tubes before commencing treatment. 
Approximately, 200 μl of blood were blotted onto a Whattman-1 filter paper, air-dried 
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and stored in sealed plastic bags for later use for extraction of DNA. The remaining  
blood samples were immediately centrifuged and the plasma aliquots were collected into 
2 ml eppendorff tubes and stored at -80 °C, the RBCs-containing pellets were 
appropriately treated and cryopreserved for further parasite analyses.   
 
2.2. Microscopy for diagnosis and estimation of parasite density.  
Preliminary diagnosis of malaria was made by quick screen of Giemsa-stained thick 
peripheral blood films. Standard techniques were used to confirm diagnosis and 
normocytemia as well as to estimate parasite density by two independent microscopists in 
duplicates of the thick and thin films. A slide was deemed negative after screening 100 
consecutive oil immersion fields of a light microscope (Olympus, Japan; Binocular 
microscope Model- CH-2; using 100x objective and l0x eye pieces). The parasite density 
per microliter (µL) of blood was calculated from the number of parasitized red blood cells 
(pRBC) per 200 white blood cells (WBC), assuming an average normal WBC count of 
8000/µL.  
 
2.3. Parasite DNA extraction, and estimation of P. falciparum multiplicity of 
infection (MOI). 
Parasite DNA was extracted from filter-papers as described elsewhere [401] with slight 
modifications. Briefly, three small discs each of an area of 6 mm3 were cut off the blood-
blotted filter paper and soaked in 1 ml 0.5 % Saponin in phosphate buffer saline (PBS) 
and incubated overnight at 4 ºC. The discs were subsequently washed for 30 minutes with 
PBS and boiled in 200 μl of 5 % Chelex-100 in water for 15 minutes.  Samples were 
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vortex-mixed and centrifuged for 2 minutes at 10,000 rpm, the supernatants were 
collected and stored at -20 ºC until use for DNA genotyping. 
The multiplicity of infection is the approximate number of parasite variants specified by 
distinct alleles of the highly polymorphic MSP-2 gene [402]. Nested polymerase chain 
reaction was used to amplify specific target sequences in MSP-2 as described elsewhere 
[403]. Briefly, in an Eppendorf thermal cycler (Mastercycler® 5330), the PCR reactions 
were carried out in a primary amplification program that involved DNA denaturation at 
95 ºC for 1 min, followed by 30 cycles of 98 ºC/10 sec, 61 ºC/20 sec/ 72 ºC/10 sec, and 
final extension for 5 min. The reaction mixture consisted of 5 μl of iProofTM high fidelity 
master mix (BIO-RAD Laboratories, Hercules, CA), 2.5 μl of the DNA extract, 0.5 μM 
of primer pairs and 2 μl of sterile distilled water. The outer primers corresponding to the 
conserved regions of block 3 of msp-2 are detailed elsewhere [404]. The second 
amplification round was similarly carried out, but with 1 μl of the initial PCR products in 
two separate tubes using allele-specific primers corresponding to the two major MSP-2 
families (IC/3D7 and FC27) [405]. The final PCR products were then subjected to 
electrophoresis on 1.5 % agarose gel loaded with ethidium bromide. Gels were 
illuminated with GelDoc-It TS 2UV transilluminator (BioDoc-ItTM imaging system, 
Upland, CA. USA) and photographed to determine number and size of DNA fragments 
presumed to represent different parasite variants. The least number of fragments of both 
alleles per sample was used as a proxy for MOI.  
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2.4. Preparation of the crude parasite antigens and determination of P. 
falciparum -specific antibody levels.  
Plasmodium falciparum parasites were maintained in continuous in vitro cultures in 
human erythrocytes (group O+) in RPMI 1640 + L-glutamine-NaHCO3 (GIBCO N.Y. 
USA) with 0.5 % albumax supplemented with Hepes, NaHCO3, gentamycin and 
hypoxanthine as described by Trager and Jensen [406]. The parasite cultures were 
synchronised with 5 % D (-) sorbitol treatment in distilled water and adjusted to 1 % 
parasitemia of mostly early trophozoites (rings) in 5-6 % hematocrit. Sonicates of late 
stage infected erythrocytes, enriched by 60 % Percoll gradient centrifugation were used 
as antigens as previously described [407]. The protein content of the crude extract was 
estimated by Bradford method [408], and the extract was aliquoted into separate sterile 
screw capped tubes and stored at – 80 ºC until use. 
Malaria specific total IgG and the subclasses, IgG1, IgG2, IgG3, and IgG4 were measured 
by an indirect ELISA, using crude antigen extract of the F32 isolate of P. falciparum.  
Briefly, flat-bottomed microtiter plates (High Binding from Costar, Cat. No. 3590 
Corning, NY 14831, USA) were coated with 50 μl/well of crude parasite antigen at 10 
μg/ml in sodium bicarbonate coating buffer and incubated at 4 ºC overnight. The plates 
were then blocked with 100 μl/well of sodium carbonate buffer (pH 9.6) containing 
0.5 % bovine serum albumin (BSA) for 2 h at 37 °C. Thereafter, the plates were washed 
with PBS supplemented with Tween-20 plus 0.15 % Kathon (Mabtech, Nacka, Sweden) 
in a microplate washer (Skan washer 300, CA, USA). After washing, 50 μl/well of serum 
samples diluted 1:400 (IgG1-4) in incubation buffer (PBS + 0.5 % BSA) were added in 
duplicates and incubated for 1 h at 37 °C.  Sera of different clinical groups were blindly 
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allocated into plates to reduce inter-plate error.  
Plates were washed as above, and bound IgG subclasses were detected with the 
respective mouse anti-human IgG1 1:1000 (SkyBio, Bedfordshire, UK), IgG2 1:3000 
(PharMingen, Erembodegem, Belgium), IgG3 1:1000 (Caltag Laboratories, Paisley, UK), 
and IgG4 1:2000 (Sigma, St. Louis, USA) and incubated for 1 h at 37 °C.  The plates 
were washed again and 50 μl of conjugated streptavidin–ALP (Mabtech) diluted 1:2000 
in incubation buffer were added and incubated for 1 h at 37 °C.  The plates were washed 
once more and developed by the addition of 50 μl/well of p-nitrophenyl phosphate 
(Sigma-Aldrich Chemie, Steinheim, Germany). The optical densities of plates were read 
at OD405 with a VmaxTM microplate reader (Molecular Devices Corporation, Menlo Park, 
USA).  Serial standard concentrations (ranging from 0.003 to 0.3 μg/ml) of IgG 
subclasses from Biogenesis (U.K) were used for the calibrations, and plasma samples 
from previously known malaria positive subjects from the Fulani tribe in Mali were used 
as positive controls. Sera from a few malaria unexposed Swedish blood donors were used 
as negative controls to assess cross-reactivity and to determine the baseline levels. The 
mean levels of IgG antibodies detected in these negative control sera were used as 
baselines above which a test sample is considered positive for the particular antibody.   
 
2.5. Extraction of human DNA and genotype of interleukin-10 (-1082A/G) SNP: 
 
Extraction of human DNA from filter-paper samples has been carried out by boiling as 
described above for parasite DNA extraction. The -1082 A/G genotype of IL-10 was 
determined by analyses of fragment length polymorphisms as described elsewhere [356]. 
Briefly, extracted DNA was amplified by PCR using sequence-specific primers (Forward; 
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5′-AAG GCA ACA CTA CTA AGG CTT CCT T-3′, and Reverse; 5′-TAA ATA TCC 
TCA AAG TTC C-3′). The PCR reaction mixture included 5 μl of 2X PCR Master Mix 
(ABgene™, Epsom, Surrey, UK), 0.25 μl of each primer, 2 μl distilled water and 3 μl of 
genomic DNA extract. The reaction was carried out in Eppendorf Mastercycle® 
(Eppendorf AG, Hamburg, Germany) with a program of initial denaturation at 95ºC/5min 
followed by 35 cycles of 95ºC/30 sec, 55ºC /30 sec, 72ºC/60 sec and final extension at 
72ºC/5 min. The PCR product was then treated with the endonuclease EcoN1 (# R0521L 
BioLab, New England) according to manufacturer instructions, and incubated at 37 ºC for 
2 hours. EcoN1 cleavage site is the underlined C in the forward primer above. The 
digested product was visualized on 1.5 % agarose gel with ethidium bromide, the length 
and number of fragments were used to identify genotypes; where the homozygous GG 
yields two fragments (280 and 310 bp), the heterozygous AG yields four fragments (310, 
280, 252, and 28 bp) and the homozygous AA yields three (310, 252 and 28 bp) 
fragments.  
 
2.6. Determination of  circulating levels of interleukin-10 . 
Circulating levels of IL-10 were determined by direct ELISA. Flat-bottomed microtiter 
plates (High Binding from Costar, Cat. No. 3590 Corning, NY 14831, USA) were coated 
with 50 μl/well of anti-human IL-10 monoclonal antibody 9D7 (Mabtech AB, Nacka, 
Sweden) diluted to 2 μg/ml in phosphate buffered saline (PBS) (pH of 7.4), and incubated 
overnight at 4 ºC. The plates were then washed twice with PBS and blocked with 100 
μl/well of 0.1 % bovine serum albumin (BSA) in PBS for two hours at room temperature. 
The plates were then washed with PBS with Tween-20 plus 0.15 % Kathon in a 
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microplate washer (Skan washer 300, Skatron Instruments, Norway). Hundred μl/well of 
sera samples [diluted 1:100 in 0.15 M Tris-Hanks] were added to 20 μl/well of Mabtech 
ELISA diluent and incubated at room temperature for 2 hours and then washed again as 
above. Then 50 μl/well of biotin-conjugated monoclonal antibody ( Mabtech 12G8 
[diluted 1:1000 in Mabtech ELISA diluent]) was added and incubated for 1 h at room 
temperature. The plates were then washed as above followed by addition of 50 μl of 
Streptavidin–ALP from Mabtech diluted 1:1000 in incubation buffer with 1% BSA and 
incubated for 1 h at room temperature. The plates were washed, developed and read using 
Molecular Devices (VmaxTM Kinetic microplate reader Menlo Park, USA) at 405 nm. 
Serial standard concentrations of (10 to 3.160 pg/ml were used for calibration, the curve 
fit was log-log = {log10(Y) = A + B * log10(X)}; where A = -01.59 is the log10 Y-intercept 
of the line of log10 (X) = 0, and B = 0.592 is the line slope. The correlation coefficient 
was 0.999. 
 
2.7. Statistical analyses. 
The data were analyzed with SPSS software version 16.0.1 (SPSS Inc., Chicago, IL, 
USA). Logistic regression analyses were used to assess differences in frequencies and 
proportions and to estimate malaria risk. Scale variables which are not normally 
distributed were log10 transformed, and differences of means were investigated by t-test 
and one way analysis of variance. Fisher’s exact test for contingency tables was used to 
test for significance in proportions of categorical data between the clinical malaria groups 
when the expected value was less than 5. 
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3. The results: 
 
3.1.  Study I. 
 
3.1.1. The demographic and clinical features of the study population.    
The total number of individuals enrolled from El-Gedarif was 177; of them 37 were 
patients with cerebral malaria (CM), 44 presented with severe malarial anemia (SMA), 55 
were patients with UM (UM) and 41 were malaria free donors (MF). The demographic 
and clinical features and parasitological indices of the study population are given in Table 
3.1.  Six patients with SMA were excluded from the current analysis because of 
insufficient plasma samples or incomplete set of data. Four of those who had CM were 
mature adults (age range 25-55 years), while all those who had SMA were young 
children mostly under five years. Individuals presenting with SMA had lower mean age 
(P = 0.002) as compared to those who had CM. Three patients (two children and one 
adult) representing 8% of those who presented with CM died within 24 hour after 
admission into hospital. Whereas parasite densities were comparable between CM and 
SMA, both groups had significantly higher parasitemia (P = 0.009 and 0.017 respectively) 
than UM. Neither the MOI nor an individual msp-2 genotype was found significantly 
different between SM and UM, or between the CM and SMA.  
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Table 3.1.  The demographic and malariological indices of the study groups. 
Study Groups  Cerebral  
Malaria  
Severe Malarial 
Anemia 
Uncomplicated 
Malaria 
Malaria Free 
Donors 
Number (female/male) 37 (14/23) 38 (12/26) 55 (25/30) 41 (12/29) 
Age years  (median, 25 and 75 percentiles)  5.0 (4.0 – 7.8) 2.75 (1.5 – 4.0) * 5.0 (3.0 – 7.0) 5.0 (2.0 - 6.8) 
Log10 parasite count. 4.4 (0.58) * 4.4 (0.48) 4.1 (0.54) -- 
Number of IC/3D7 alleles 1.7 (0.2) 1.4 (0.2) 1.6 (0.2) -- 
Number of FC27 alleles 2.1 (0.2) 1.8 (0.2) 2.2 (0.2) -- 
Multiplicity of infection  (MOI) 2.0 (1.2) * 1.5  (0.9) 2.2  (1.2) -- 
Except for age, all values are given as mean (SD), and * significant values are discussed in the text. 
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3.1.2. Correlation of IgG antibodies with age, parasite density, MOI and msp-2 
genotypes in the study population. 
Pearson’s correlation analysis showed significant positive association between age and total IgG 
(r = 0.266, P = 0.001), IgG1 (r = 0.299, P < 0.001), IgG2 (r = 0.459, P < 0.001) and IgG3 (r = 
0.350, P < 0.001) but not with IgG4 (r = 0.132, P = 0.089) in all study groups.  
In an age adjusted analysis, the parasite density correlated significantly inversely with total IgG 
(r = -0.260, P = 0.006), IgG1 (r = -0.287, P < 0.002), IgG2 (r = -0.204, P = 0.033) and IgG3 (r 
= -0.205, P = 0.031), but did not correlate with IgG4 (r = -0.06, P = 0.53). In contrast, no 
significant correlation could be found between any Ab levels and neither MOI nor the number 
of individual msp-2 genotypes (IC-1 or FC27). The correlation between the levels of individual 
IgG subclasses and the total IgG concentrations was  significant and supports the accuracy of 
the results (not listed). 
 
3.1.3. Comparison of  IgG antibody subclass levels between study groups.  
The overall comparison of levels of total and subclass IgG antibodies as shown in figures 3.1 
and 3.2  revealed higher levels of IgG1 and IgG3 subclasses in the whole study population 
regardless of the clinical group. The levels of these two antibody subclasses were highly 
variable both between and within study groups. The pair-wise comparisons of mean antibody 
levels between the study groups revealed higher levels of total IgG (P < 0.001), IgG1 (P = 0.001) 
and IgG3 (P < 0.001) but not IgG2 and IgG4 in all malaria patients (SM and UM) compared to 
the MF individuals. Further age-adjusted analyses splitting malaria patients into SM and UM 
revealed that there were lower levels of total IgG (P = 0.001), IgG1 (P = 0.004) and IgG4 (P = 
0.023), but not IgG2 or IgG3 in the SM compared to UM.  
Re-analysis of data splitting the SM group into CM and SMA showed comparable levels of total 
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IgG (P = 0.15), IgG2 (P = 0.17), IgG3 (P = 0.30) and IgG4 (P = 0.43) but not of the IgG1 (P = 
0.034) subclass in SMA and CM. However, the difference in IgG1 levels between these groups 
disappeared after adjustment for age (P = 0.33). The SMA patients had lower levels of total IgG, 
(P = 0.002), IgG1 (P = 0.004) and IgG4 (P = 0.031) compared to those with UM, whereas the 
levels of all IgG subclasses did not differ significantly between CM and UM. Noteworthy, the 
differences between the groups of SMA and UM remained significant in the levels of total IgG 
(P = 0.009), IgG1 (P = 0.03) and IgG4 (P = 0.019) after adjustment for both age and parasite 
density. 
Association of risk of SM and levels of total IgG, IgG1 and IgG4 was carried out by calculating 
the odds ratio of the prevalence of negative versus positive sera for the specific antibody among 
the SM compared to UM as shown in Table 3.2.  There was significantly lower prevalence of 
IgG1 (P = 0.01) and IgG4 (P = 0.002) reactive sera among the group of SM compared to UM. 
However, there were no significant differences in the prevalence of total IgG, IgG2 and IgG3 
between these two groups.  
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Figure 3.1.  General comparisons of IgG total and subclass levels within and between 
different study groups of severe malaria (SM), uncomplicated malaria (UM) and malaria free 
donors (MF).    
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Figure 3.2.   Comparisons of IgG total and subclass levels within and between groups of 
cerebral malaria (CM), severe malarial anemia (SMA) and uncomplicated malaria (UM). 
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Table 3.2. Antimalarial immunoglobulin-G subclass sera reactivity and risk of severe malaria. 
Antibody Reactivity* Severe 
malaria 
Uncomplicated 
malaria 
Total  OR 95 % CI  P value 
IgG1 Negative 23 (31.1 %) 6 (10.9 %) 29 (22.5 %) 3.68 1.38 – 9.54  0.010 
 Positive  51 (68.9 %) 49 (89.1 %) 100 (77.5 %) 0.27 0.11 – 0.71 
      
IgG2 Negative 27 (36.5 %) 16 (11.1 %) 43 (33.6 %) 1.36 0.65 – 2.87 0.453 
 Positive  47 (63.5 %) 38 (88.9 %) 85 (66.4 %) 0.73 0.35 – 1.55 
      
IgG3 Negative 1 (1.4 %) 3 (5.5 %) 4 (3.1 %) 0.24 0.03 – 1.75 0.314 
Positive  72 (98.6 %) 52 (94.5 %) 124 (96.9 %) 4.15 0.57 – 29.66 
      
IgG4 Negative 46 (63 %) 19 (35.2 %) 65 (51.2 %) 3.14 1.51 – 6.51 0.002 
Positive  27 (37 %) 35 (64.8 %) 62 (48.8 %) 0.32 0.15 – 0.66 
      
Total IgG Negative# 1 (1.4 %) 0 (0.0%) 1 (0.8 %) 1.73 0.15 – 19.79 0.418 
Positive  71 (98.6 %) 51 (100 %) 122 (99.2 %) 0.58 0.05 – 6.68 
      
* Antibody level greater than the cut-off point established as the average level measured in sera from malaria unexposed donors was 
considered positive.  OR = Odds ratios and CI represents Confidence Interval. 
 # Continuity correction was made to eliminate the zero count of negative IgG total sera among persons with uncomplicated malaria, 
(1/(R+1) and (R/(R+1) were respectively added to counts of SM and UM in total IgG, where R = the total number of SM/ total number 
of UM = 72/51.  
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3.2. Study II. 
 
3.2.1. The demographic and malariological indices of the study groups. 
The total number of individuals investigated in this study was 352 including 171 individuals 
from the samples collected in El-Gaderif during season 2003 and the rest were from El-Obied 
and the villages around the city during 2006. Those who were enrolled from El-Obied included 
4 patients with CM, 23 with SMA, 82 with UM, and 72 were MF. The sex frequency, age and 
clinical classification of study II population are shown in Table 3.3.   
For the overall study population, there are no significant differences in age and sex frequencies 
between the different clinical groups.  
 
3.2.2. The circulating levels of interleukin-10 in the different study groups. 
The distribution of the levels of IL-10 was positively skewed, thus scores of IL-10 concentration 
were log transformed to improve normality. One way analysis of variance (ANOVA) revealed 
significant differences in the circulating IL-10 between the different clinical groups (F = 7.1, P 
< 0.001) (Figure 3.3). Tukey’s post hoc analysis, showed significantly lower concentrations of 
IL-10 in CM patients as compared with the MF donors (P = 0.001) or with UM patients (P < 
0.001).  Although not significant, patients with SMA have had lower IL-10 levels compared to  
those with UM or the MF donors separately, however, SMA patients had slightly higher levels 
of IL-10 than patients with CM. Interestingly, there was an inverse correlation between IL-10 
levels and the degree of fever indicated by the body temperature (1-tailed P = 0.009) (data not 
shown). No correlation was observed between IL-10 levels and the patient age or parasitemia 
separately. 
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2.1.1. The frequencies of alleles and genotypes in interleukin-10 (-1082 A/G) single 
nucleotide polymorphism. 
Of the total number of samples compiled from the two sites, we could extract sufficient DNA 
and genotyped the SNP (-1082 A/G) for 226 samples. The Hardy-Weinberg distribution of 
alleles and genotypes among different clinical groups and the estimation of risk of severe 
malaria incurred by carriage of a specific allele or genotype of the -1082 SNP are given in 
Tables 3.4 and 3.5.  The allele distribution among the patients of CM but not SMA or UM 
deviated significantly from Hardy-Weinberg Equilibrium (HWE). The possible gene-phenotype 
interactions and outcomes of either allelic or genotypic constitution on malaria outcome are 
given in Table 3.5. Because it is inapplicable in this situation, we excluded the multiplicative 
genetic model assuming a risk weight (r) for the heterozygous and (r2) for homozygous 
candidate allele [409]. The alternative additive model assuming a risk weight (r) for the 
heterozygous and (2r) for homozygous, were used to test the hypothesis that carrying the G 
allele influences the risk of CM.  Further analysis of the latest model assuming dominant or 
recessive modes of the allele inheritance was performed by pooling the genotypes into different 
models (Table 3.5).     
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Table 3.3.  Demographic features of study II population 
Clinical groups (CM)  (SMA)  (UM)  (MF) Total 
Number (Female + Male). 
 
41 (16 + 25) 61 (22 + 39) 137 (56 + 81 M) 113 (47 + 66) 352 (141 + 211 ) 
Age in years, mean (SD). 
 
4.86  (2.41) 
 
3.28 (2.63) 
 
4.40  (2.89) 
 
4.27 (2.40)  
 
4.21 (2.75) 
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Table 3.4.  The Hardy-Weinberg Equilibrium for the interleukin-10 (-1082 A/G) SNP in the study groups . 
Patients groups IL-10 genotype Allele frequency (A:G) %  
 P values *.  AA AG GG Total 
Cerebral Malaria . 15 8 12 35 54.3 : 45.7  0.006. 
Severe Malarial Anemia . 18 20 14 52 53.8 : 46.2 0.264  
Uncomplicated Malaria. 42 54 25 121 56.2 : 43.8 0.616 
Malaria free donors. 07 08 03 18 61.1 : 38.9 0.961 
Total study population 82 90 54 226 56.2 : 43.8  0.016  
 * Chi Square test with 2 df, P value less than 0.05 indicates inconsistency with Hardy-Weinberg Equilibrium. 
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Table 3.5.  Estimation of odds ratios, assuming different modes of A/G alleles inheritance. 
Allele/Genotype SM (n) UM (n) Total OR  (95.0% C.I.) P value * 
1.  Co-dominant inheritance   
A 83 137  220 1.18 (0.79 to 1.78) 0.42 
G 71 99 170 0.84 (0.56 to 1.27) 
Total 154 236 390 - - 
2.  Dominant  G allele inheritance.   
AA 30  47 77 1.04  (0.58 to 1.87) 0.90 
AG + GG 47 71 118 0.96 (0.54 to 1.74) 
Total 77 118 195 - - 
3. Recessive  G allele inheritance.   
AA +AG 53 90 143 4.67 (2.69 to 8.09) 0.32 
GG 24 28 52 0.69 (0.36 to 1.31) 
Total 77 118 195 - - 
* Pearson Chi-Square test comparing the frequencies among patients with severe malaria (SM) and uncomplicated malaria (UM) revealed no 
significant risk SM  being associated with any of the alleles or genotypes of -1082 A/G single nucleotide polymorphism in IL-10.  
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Figure 3.3 Levels of circulating IL10 in different clinical groups of malaria patients and 
healthy controls, box and error bars show the median and 95% CI of circulating IL-10 levels in 
the cerebral malaria (CM), severe malaria anemia (SMA), uncomplicated malaria (UM) and 
malaria free donors (MF). 
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Chapter Four  
 
Discussion and conclusions  
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4.1 Discussion. 
 
 
4.1.1. Study I. 
 
In study I, as previously noted in responses to many malaria antigens investigated elsewhere 
[410-412], the relative abundance of IgG subclasses was profoundly altered, being largely 
dominated by IgG1 and IgG3. There were higher levels of IgG1 and IgG3 compared to IgG2 
and IgG4 in all individuals investigated regardless of the clinical status. Except for IgG2, there 
were prominent increases in levels of all IgG antibodies in infected individuals compared to the 
MF donors. The rise in levels of IgG antibodies in the infected individuals is obvious as current 
parasitemia induces the antibody production. However, the similar levels of IgG2 in the patients 
and the malaria free individuals cannot be explained as a response to the current infection, rather 
it may indicate the intensity of P. falciparum transmission during the specified period. Worth 
mentioning; we collected the samples towards the end of the rainy season after a notably intense 
transmission season.  
In spite of the altered natural balance of IgG subclasses serum levels, and apart from the notable 
differences between the study groups, we could still detect a clear age-dependent increase in the 
levels of all IgG subclasses except IgG4. This age associated elevation of IgG levels concurs 
with the well known age-dependent evolution of protection from malaria [306, 378]. However, 
the lack of association between IgG4 and age in this analysis might partly be explained by the 
relatively young age of the children investigated hence the limited exposure to parasite. 
Interestingly, the IgG4 antibodies which are known to be induced by chronic infections [413, 
414], might reflect the development of  immune memory as a result of cumulative exposure to 
different parasite strains including the relatively common variants presumed to cause severe 
malaria. Accordingly, the elevated levels of IgG4 detected in infected individuals as compared 
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to the MF donors, are clearly associated with the current infection. However, this response 
might have been induced by Th-2 polarized T-cell responses. This is supported by reports 
demonstrating the induction of IgG4 by interleukin-4 (IL-4) [415, 416].  
The effect of parasite density on the levels of anti-malaria IgG antibodies might not be straight 
forward due to variation in the parasite antigenic characteristics and sequestration in micro 
capillaries. However, in this study, we observed significant negative associations between the 
parasite density and the levels of all IgG antibodies except IgG4. All of these associations were 
age-independent, with IgG1 exhibiting the stronger association as compared to IgG2 and IgG3. 
The inverse associations of IgG1 and IgG3 with the parasite density are in line with the well 
established anti-parasite effects of these anti-malarial antibodies. However, the association 
between IgG2 and parasite densities reveals an unusual anti-parasite effect for this subclass. 
This is interesting, because unlike the primarily cytophilic IgG1 and IgG3, IgG2 antibodies do 
not bind the common Fc receptor (FcR) types that mediate the antibody-dependent cellular 
cytotoxicity. Thus, the observed anti-parasite effect of IgG2 may be mediated through a mutated 
type of FcRII which was shown to be common in this population [417].   
The specific role of IgG4 antibodies in malaria protection and/or pathogenesis is not well 
understood. Only a weak non significant negative association of IgG4 with parasite density was 
observed, indicating little if any anti-parasite activity in this subclass. However, the increased 
risk of SM associated with the low prevalence of IgG1 and IgG4 antibodies in this study 
suggests a protective role for these two subclasses against SM. Pair-wise comparisons of the 
mean levels of IgG antibodies between the groups of SM, UM, and MF, and subsequently after 
splitting the group of SM into CM and SMA provided further support for different levels of 
IgG1 and IgG4 in SM and UM. While levels of all IgG antibodies are comparable between CM 
and SA, the combined SM group had significantly lower levels of total IgG, IgG1 and IgG4 than 
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those with UM. Although all these differences persisted after adjustment for age, only the 
difference in total IgG and IgG4 remained significant after inclusion of both age and the parasite 
density as covariates indicating a marked effect of parasite density on production of IgG1 but 
not total IgG and IgG4. Taken together, the associations of the low prevalence and levels of 
IgG1 and IgG4 antibodies with SM indicate important protective effect for these subclasses 
against SM, and whereas the protective effect of IgG1 may largely be due to its known anti-
parasite action, the presumed protective role of IgG4 against SM may be attributed to the clearly 
evidenced anti-inflammatory effect of IgG antibodies [418, 419]. Although the anti-
inflammatory role of IgG4 is proved in its clinical use for the treatment of autoimmune diseases, 
it remains to be demonstrated whether antimalarial IgG4 undergo Fab arm exchange that 
provides the basis for the anti-inflammatory activity attributed to these antibodies [419]. Several 
lines of evidence argue for a possible role for this anti-inflammatory activity of IgG4 in 
protection from severe complications of malaria. For instance, the protection from SM conferred 
by infection with helminthes [420, 421]. The increased levels of IgG4 associated with 
helminthes infection might be the underlying cause of the observed protection from clinical 
malaria. Moreover, IgG4 antibodies are poorly recognized by Fc receptors, thus , do not 
stimulate inflammation or activate the complement system, rather they were shown to inhibit the 
complement activation [422]. The mechanisms by which IgG4 mediate anti-severe malaria 
effects is not understood. However, unlike other antibodies IgG4 exist in vivo as monovalent, 
bispecific molecules, and are also capable of Fc-Fc interaction with other IgG antibodies [423]. 
Accordingly, we speculate that, IgG4 may directly block the binding of the cytophilic-antibody-
containing immune complexes to the effector cells. Alternatively, IgG4 may cause the formation 
of small, non precipitating immune complexes that do not induce inflammatory responses.  
In conclusion, the results of study I are not only revealing significant difference in IgG1 and 
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IgG4 levels and prevalence between SM and UM but also indicate an important anti-severe 
malaria protective effect. Thus, it is obvious that factors other than age and parasite density are 
involved in determining the serum levels of the anti-malaria IgG2 and IgG4 antibodies. In 
addition to the intensity of P. falciparum transmission other factors such as the number of 
previous clinical episodes, the genetic background of the host and the parasite strains might also 
influence the mechanisms regulating serum levels of these antibody subclasses.  
 
4.2. Study II. 
 
 
In humans, the role of IL-10 in malaria is less well defined. It seems to be down-regulating the 
immunopathology underlying complicated malaria. High circulating levels of IL-10 have 
repeatedly been associated with SM in Thailand [226], Guinea [281],  Mali [245] and Senegal 
[308]. Interestingly,  in contrast to these, our current data showed low levels of circulating IL-10 
in both groups of severe malaria (CM and SAM) as compared to those with UM or to HCs. The 
decrease in IL-10 levels was particularly prominent in the patients of CM. This observation is so 
far consistent with the suggested protective role of IL-10 previously demonstrated in mice 
models [307, 392, 424] and accords with a similar finding reported in deeply comatose adult 
Vietnamese patients with CM [282]. However, it contradicts many previous reports of elevated 
IL-10 during CM. This contradiction can be justified on the basis of different methodology and 
inclusion criteria of participants in these studies as well as variation in pattern of malaria 
transmission in the different epidemiological settings of these studies. Moreover, the  immune 
competency, and human genetic variation in the studied populations might have also contributed 
to these contradicting results.  
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According to these data, it could be speculated that CM might have arisen as a result of 
uncontrolled pro-inflammatory responses, and that CM patients would have defective IL-10 
production.  
The link between the circulating IL-10 levels and SMA is not well understood. Previous studies 
have linked SMA with relatively low levels of IL-10 in African children [196, 198, 425]. 
However, this is contradicted by other reports of high IL-10 during SMA [212]. Since many 
previous reports have associated SMA with increased levels of proinflammatory cytokines such 
as TNF-α and IFN-γ which were suggested to enhance immune mediated destruction of both 
infected and non-infected RBCs and to suppress the erythropoiesis, it is likely that elevated 
levels of IL-10 through down-regulating inflammatory processes play a protective rather than 
deleterious role in SMA. However, this speculation does not go with the recent finding that high 
IL-10 is associated with inefficient clearance of P. falciparum which could as well lead to 
persistent parasitemia and severe malaria [305, 309]. Yet, it can still be argued that the role of 
IL-10 in the immuno-pathogenesis of SMA could be of dual nature, and that the temporal and 
balanced production of IL-10 rather than the absolute levels of this cytokine are  the crucial 
factors in determining the outcome of malaria infection.   
Investigation of how the allelic variants and genotypes of the -1082 A/G SNP of IL-10 relate to 
the clinical forms of malaria revealed no significant association between the risk of severe 
malaria and any allele or genotypes of this specific SNP (Tables 3.4 and 3.5). Interestingly, tests 
for the Hardy-Weinberg Equilibrium (HWE) revealed significant deviation from the expected 
frequencies among the patients with CM (P<0.006) while the distribution of geneotypes was 
conforming with HWE among the other patients who presented with SMA or UM as well as the 
few MF donors who were analyzed.  
Logistic regression analysis of the allele frequencies within clinical groups (Table 3.5) revealed 
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no significant association between any of the alleles and a particular form of clinical 
presentations, but a non-significant trend of decreased homozygous GG genotypes can be 
observed among the all patient groups. However, due to lack of information about the frequency 
of these specific alleles and genotypes among the Sudanese population, it is not possible to draw 
conclusion about how this SNP relates to malaria pathogenesis.  
Taking into account the previous reports of higher productivity of IL-10 by the homozygous GG 
[347, 358, 396, 426, 427], it was interesting to  assess how the G allele relates to the circulating 
levels of IL-10 in the different clinical groups. Comparison of mean levels of IL-10 between the 
different genotypes across different clinical groups revealed no significant differences between 
the carriers of either allele (data not shown). However, the homozygous GG individuals had 
slightly higher levels of IL-10 among the patients of UM, but surprisingly, lower levels in 
patients of CM.  In general it could also be suggested that genetic background and haplotypic 
patterns rather than individual SNPs may be the cause of variable IL-10 production and 
eventually protection from and/or susceptibility to severe malarial diseases in different humans 
[375].  
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4.3. Conclusions. 
 
• The present data reveal significant differences in the levels of IgG1 and IgG4 among 
between patients who presented with severe malaria as compared to those with 
uncomplicated malaria, indicating a protective effect for these antibody subclasess 
against severe malaria.  
 
• The multiplicity of infection (MOI) defined as the number of different Plasmodium 
falciparum clones showed no significant effect on the circulating levels of IgG 
antibodies, and the number of parasite clones were similar in the different patient groups. 
 
• The IL-10 levels in children with CM were significantly lower than in those with 
uncomplicated malaria, and IL-10 was particularly lower in comatose patients as 
compared to other forms of clinical malaria, indicating a protective role for IL-10 against 
severe malaria. 
 
• There was no significant association between the different alleles in the IL-10 gene SNP 
at position -1082 and the various clinical forms of  malaria, and no specific allele or 
genotype was associated with serum levels of IL-10. 
 
 
4.4. Perspectives. 
 
Future plans include investigating: 
• Genetic factors determing susceptibility/resistance to severe malaria, particularly severe 
malaria anemia among sympatric tribes (Fulani, Nuba and Hawzma) living in Kordofan 
region in the middle west of Sudan.   
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